Olga BelosludovaOlgaBelosludova

Represented a major Japanese medical device company in a high-stakes DOJ investigation, successfully resulting in all charges being dropped.

Conducted over 17 internal investigations for a global life sciences company involving complex compliance issues, including FCPA violations, antitrust concerns and off-label promotion risks.

Represented a major U.S. medical device company in a voluntary disclosure to the DOJ regarding the misuse of external funding.

Conducted a sensitive internal investigation for a major Japanese manufacturer regarding management-level misconduct at its U.S. subsidiary reported by a whistleblower.

Conducted a sensitive investigation for a major U.S. media and entertainment company to assess legal risks posed by a terminated employee, resulting in the withdrawal of all claims.

Led a proactive market review of bribery risks for the Japanese subsidiary of a U.S. life sciences company.

Advised major global companies — including a U.S. cybersecurity firm, a cloud software provider and a multinational entertainment company — on crisis response for ongoing cyberattacks and data breaches, including mandatory disclosures to the Japanese Personal Information Protection Commission (PPC).

Advised a major U.S. bank on Japanese data privacy regulations for its SaaS product, focusing on cross-border transfer of PII from Japan to the U.S.

Advised various financial institutions, including a major U.S. cryptocurrency exchange, on regulatory licensing requirements for operating as a cryptocurrency exchange operator in Japan.

Advised a global payment services company on the implications of amendments to relevant laws, including Japanese anti-money laundering (AML) laws, for its market entry of a new product.

Advised a major U.S. growth equity firm on regulatory requirements for its portfolio company to provide cross-border payment services in Japan.

Advised a NASDAQ-listed U.S. life sciences company on clinical trial agreements with physicians in Japan.

Advised a U.S. biopharmaceutical company on regulatory compliance under Japanese pharmaceutical laws regarding the hosting of medical seminars and promotional events.

Advised a major U.S. life sciences manufacturer on reviewing third-party consulting reports to ensure accurate description of U.S. ESG laws.

Advised a U.S. marketer and distributor of diagnostic tests on a contract dispute with a Japanese manufacturer, including interpretation issues under Japanese law.

Advised a global e-discovery company on litigation risks associated with workforce restructuring, including termination of contractors and management-level officers.

Advised a global social media platform on various sensitive HR compliance issues, including risks associated with converting contractors to full-time employees and disciplinary measures under Japanese labour law.

Advised a major global manufacturer headquartered in Japan on its reduction in force (RIF) strategies and execution.

Assisted a European holding company with the sensitive process of resignation and appointment of new directors for its Japanese subsidiary.

Appointed as an External Collaborator for the International Labour Organization in February 2026 to analyze legal, administrative and practical frameworks for occupational safety and health (OSH) recording and notification systems across the Asia-Pacific region, focusing on compliance with ILO standards.

Appointed as an External Collaborator for the International Labour Organization in May 2021 and proactively supported the Responsible Supply Chains in Asia programme until May 2022.

Key member of the team representing a major Japanese pharmaceutical company in securing a multibillion-dollar victory in an ICC arbitration against a European pharmaceutical company.

Advised a publicly listed Japanese construction equipment company on document production strategies during arbitration, specifically handling documents containing PII.